The power of genetic diversity in genome-wide association studies of lipids. Vujkovic M, Ramdas S, Lorenz KM, Guo X, Darlay R, Cordell HJ, He J, Gindin Y, Chung C, Myers RP, Schneider CV, Park J, Lee KM, Serper M, Carr RM, Kaplan DE, Haas ME, MacLean MT, Witschey WR, Zhu X, Tcheandjieu C, Kember RL, Kranzler HR, Verma A, Giri A, Klarin DM, Sun YV, Huang J, Huffman JE, Townsend Creasy K, Hand NJ, Liu CT, Long MT, Yao J, Budoff M, Tan J, Li X, Lin HJ, Chen YI, Taylor KD, Chang RK, Krauss RM, Vilarinho S, Brancale J, Nielsen JB, Locke AE, Jones MB, Verweij N, Baras A, Reddy KR, Neuschwander-Tetri BA, Schwimmer JB, Sanyal AJ, Chalasani N, Ryan KA, Mitchell BD, Gill D, Wells AD, Manduchi E, Saiman Y, Mahmud N, Miller DR, Reaven PD, Phillips LS, Muralidhar S, DuVall SL, Lee JS, Assimes TL, Pyarajan S, Cho K, Edwards TL, Damrauer SM, Wilson PW, Gaziano JM, O'Donnell CJ, Khera AV, Grant SFA, Brown CD, Tsao PS, Saleheen D, Lotta LA, Bastarache L, Anstee QM, Daly AK, Meigs JB, Rotter JI, Lynch JA, Regeneron Genetics Center, Geisinger-Regeneron DiscovEHR Collaboration, EPoS Consortium, VA Million Veteran Program, Rader DJ, Voight BF, Chang KM. LIPOPROTEINS AND ATHEROGENESIS IN TRANSGENIC ANIMALS NIH P01HL018574 Apr 1, 1976 - Role: Principal InvestigatorĪdministrative Core - Pharmacogenomics of Statin Therapy (POST) NIH/NIGMS P50GM-01 Role: Principal InvestigatorĪ multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. PEDIATRIC CLINICAL RESEARCH CENTER NIH M01RR001271 Dec 1, 1981 - Role: Co-Investigator PLASMA LIPOPROTEINS IN CORONARY ARTERY DISEASE NIH R01HL033577 Dec 1, 1984 - Role: Principal Investigator The Southwest National Primate Research Center NIH P51RR013986 Jun 1, 1999 - Role: Co-Investigator Pharmacogenomics and Risk of Cardiovascular Disease NIH U01HL069757 Sep 27, 2001 - Role: Principal InvestigatorĬOMPARATIVE GENOMIC ANALYSIS OF CARDIOVASCULAR GENE REGU NIH U01HL066691 Sep 30, 2000 - Role: Principal Investigator Pharmacogenomics and Risk of Cardiovascular Disease NIH U19HL069757 Sep 27, 2001 - Role: Principal Investigator
NCMHD Center of Excellence in Nutritional Genomics NIH P60MD000222 Jan 15, 2003 - Role: Co-Investigator HMG-CoA reductase alternative splicing and LDL response to statin NIH R21HL093507 Jul 1, 2009 - Role: Principal Investigator Genetic and Molecular Approaches To Cardiovascular Disease NIH T32HL098057 Sep 1, 2009 - Role: Principal Investigator Saturated Fat and Protein Effects on Atherogenic Dyslipidemia NIH R01HL106003 Aug 18, 2011 - Role: Principal InvestigatorĮffects of resistant starch on lipid and glucose metabolism in insulin resistance NIH RC1DK086472 Sep 30, 2009 - Role: Co-Principal Investigator Genetic Etiology of Cancer Drug Response NIH R01CA161608 Mar 1, 2012 - Role: Co-Principal Investigator Pharmacogenomics of Statin Therapy NIH P50GM115318 Sep 7, 2015 - Role: Principal Investigator Statin Treatment and Incident Alzheimer's Disease and Related Dementias in a Large, Multi-ethnic Health Plan NIH RF1AG069259 Sep 1, 2020 - Role: Co-Principal Investigator Functional significance of genetic findings is being evaluated in appropriate human cellular and animal models, with the goal of connecting genotypes to clinically relevant determinants of cardiovascular disease risk. Multiple statin-treated population samples are being examined to test the reproducibility and generalizability of findings derived from both candidate gene and genome-wide searches for SNP associations with markers of statin efficacy as well as muscle toxicity. A major current research emphasis has been the identification of genetic determinants of the wide range of inter-individual variability in phenotypic and clinical response to statin treatment. His laboratory developed and applied methodology that led to the discovery of a common genetically-influenced atherogenic lipoprotein phenotype that underlies cardiovascular disease risk in patients with obesity, type 2 diabetes, and metabolic syndrome. Krauss' research program focuses on plasma lipoprotein metabolism and related traits that influence risk for coronary artery disease.
0 kommentar(er)
